TrialThe oncologist2021
A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.
William Jeffery Edenfield et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled ittrialcites it